Newton, MA – According to filings with the U.S. Securities and Exchange Commission, Abcuro is raising $20,000,000.00 in new funding. Sources indicate as part of senior management President, Stefano Gulla played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Abcuro

A nimble group of medical experts, industry leaders and experienced entrepreneurs focused on delivering innovative therapies to patients. We take a patient-centric approach to identify dysfunctional immune pathways, validate their role in disease and discover new therapies to modulate their function. we are developing first-in-class immunotherapies to treat autoimmunity and cancer.

To learn more about Abcuro, visit http://www.abcuro.com/

Contact:
Stefano Gulla, President
401-591-6793
stefano.gulla@abcuro.com
https://www.linkedin.com/in/stefano-gull%C3%A0-2bb65a4/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved